Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in three upcoming conferences in September during which he will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday, September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m. Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas Weisel Partners Healthcare Conference and Citi Biotech Day will be available for 10 business days following each conference. Each webcast can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 18, 2017 Kurzlehrgang mit ... adoptiven Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei ... ... wird Dr. Yoav Peretz , Scientific Director bei ... von Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien ...
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting ... be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). ... provide an opportunity to interact with peers, make new connections and talk bio biz. ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
Breaking Biology News(10 mins):